138 results on '"Stoker, J."'
Search Results
2. The effectiveness of immediate versus delayed tubal flushing with oil-based contrast in women with unexplained infertility (H2Oil-timing study): study protocol of a randomized controlled trial
- Author
-
Kamphuis, D., Rosielle, K., van Welie, N., Roest, I., van Dongen, A. J.C.M., Brinkhuis, E. A., Bourdrez, P., Mozes, A., Verhoeve, H. R., van der Ham, D. P., Vrouenraets, F. P.J.M., Risseeuw, J. J., van de Laar, T., Janse, F., den Hartog, J. E., de Hundt, M., Hooker, A. B., Huppelschoten, A. G., Pieterse, Q. D., Bongers, M. Y., Stoker, J., Koks, C. A.M., Lambalk, C. B., Hemingway, A., Li, W., Mol, B. W.J., Dreyer, K., and Mijatovic, V.
- Published
- 2023
- Full Text
- View/download PDF
3. The awareness of radiologists for the presence of lateral lymph nodes in patients with locally advanced rectal cancer: a single-centre, retrospective cohort study
- Author
-
Sluckin, T. C., Rooker, Y. F. L., Kol, S. Q., Hazen, S. J. A., Tuynman, J. B., Stoker, J., Tanis, P. J., Horsthuis, K., and Kusters, M.
- Published
- 2022
- Full Text
- View/download PDF
4. Mesenchymal stem cell therapy for therapy refractory complex Crohn’s perianal fistulas: a case series
- Author
-
Pronk, A. J. M., primary, Beek, K. J., additional, Wildenberg, M.E., additional, Bemelman, W. A., additional, Stoker, J., additional, and Buskens, C. J., additional
- Published
- 2024
- Full Text
- View/download PDF
5. [18F]FDG-PET/CT-based risk stratification in women with locally advanced uterine cervical cancer
- Author
-
Adam, J.A., primary, Poel, E., additional, van Eck Smit, B.L.F., additional, Mom, C.H., additional, Stalpers, L.J.A., additional, Laan, J.J., additional, Kidd, E., additional, Stoker, J., additional, and Bipat, S., additional
- Published
- 2024
- Full Text
- View/download PDF
6. Oil-based versus water-based contrast media for hysterosalpingography in infertile women of advanced age, with ovulation disorders or a high risk for tubal pathology: study protocol of a randomized controlled trial (H2Oil2 study)
- Author
-
Rosielle, K., Kamphuis, D., van Welie, N., Roest, I., Mozes, A., van Santbrink, E. J. P., van de Laar, T., Hooker, A. B., Huppelschoten, A. G., Li, W., Bongers, M. Y., Stoker, J., van Wely, M., Koks, C., Lambalk, C. B., Hemingway, A., Mol, B. W. J., Dreyer, K., and Mijatovic, V.
- Published
- 2022
- Full Text
- View/download PDF
7. Recurrent disease detection after resection of pancreatic ductal adenocarcinoma using a recurrence-focused surveillance strategy (RADAR-PANC): protocol of an international randomized controlled trial according to the Trials within Cohorts design.
- Author
-
Daamen, L. A., van Goor, I. W. J. M., Groot, V. P., Andel, P. C. M., Brosens, L. A. A., Busch, O. R., Cirkel, G. A., Mohammad, N. Haj, Heerkens, H. D., de Hingh, I. H. J. T., Hoogwater, F., van Laarhoven, H. W. M., Los, M., Meijer, G. J., de Meijer, V. E., Pande, R., Roberts, K. J., Stoker, J., Stommel, M. W. J., and van Tienhoven, G.
- Subjects
RANDOMIZED controlled trials ,PANCREAS ,PATIENT experience ,PANCREATIC duct ,LEGAL evidence ,TUMOR markers ,PANCREATIC cancer - Abstract
Background: Disease recurrence remains one of the biggest concerns in patients after resection of pancreatic ductal adenocarcinoma (PDAC). Despite (neo)adjuvant systemic therapy, most patients experience local and/or distant PDAC recurrence within 2 years. High-level evidence regarding the benefits of recurrence-focused surveillance after PDAC resection is missing, and the impact of early detection and treatment of recurrence on survival and quality of life is unknown. In most European countries, recurrence-focused follow-up after surgery for PDAC is currently lacking. Consequently, guidelines regarding postoperative surveillance are based on expert opinion and other low-level evidence. The recent emergence of more potent local and systemic treatment options for PDAC recurrence has increased interest in early diagnosis. To determine whether early detection and treatment of recurrence can lead to improved survival and quality of life, we designed an international randomized trial. Methods: This randomized controlled trial is nested within an existing prospective cohort in pancreatic cancer centers in the Netherlands (Dutch Pancreatic Cancer Project; PACAP) and the United Kingdom (UK) (Pancreas Cancer: Observations of Practice and survival; PACOPS) according to the "Trials within Cohorts" (TwiCs) design. All PACAP/PACOPS participants with a macroscopically radical resection (R0-R1) of histologically confirmed PDAC, who provided informed consent for TwiCs and participation in quality of life questionnaires, are included. Participants randomized to the intervention arm are offered recurrence-focused surveillance, existing of clinical evaluation, serum cancer antigen (CA) 19–9 testing, and contrast-enhanced computed tomography (CT) of chest and abdomen every three months during the first 2 years after surgery. Participants in the control arm of the study will undergo non-standardized clinical follow-up, generally consisting of clinical follow-up with imaging and serum tumor marker testing only in case of onset of symptoms, according to local practice in the participating hospital. The primary endpoint is overall survival. Secondary endpoints include quality of life, patterns of recurrence, compliance to and costs of recurrence-focused follow-up, and the impact on recurrence-focused treatment. Discussion: The RADAR-PANC trial will be the first randomized controlled trial to generate high level evidence for the current clinical equipoise regarding the value of recurrence-focused postoperative surveillance with serial tumor marker testing and routine imaging in patients after PDAC resection. The Trials within Cohort design allows us to study the acceptability of recurrence-focused surveillance among cohort participants and increases the generalizability of findings to the general population. While it is strongly encouraged to offer all trial participants treatment at time of recurrence diagnosis, type and timing of treatment will be determined through shared decision-making. This might reduce the potential survival benefits of recurrence-focused surveillance, although insights into the impact on patients' quality of life will be obtained. Trial registration: Clinicaltrials.gov, NCT04875325. Registered on May 6, 2021. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
8. DOP77 Mesenchymal stem cell therapy for refractory Crohn’s perianal fistulas: a case series
- Author
-
Pronk, A, primary, Beek, K J, additional, Wildenberg, M E, additional, Bemelman, W A, additional, Stoker, J, additional, and Buskens, C J, additional
- Published
- 2024
- Full Text
- View/download PDF
9. P243 Multi-modality intestinal ultrasound is accurate and reproducible to distinguish inflammatory from chronic fibrotic strictures in Crohn’s disease – results from the STRICTURE study
- Author
-
de Voogd, F, primary, Pruijt, M, additional, Beek, K, additional, Van Rijn, K, additional, Van der Bilt, J, additional, Buskens, C, additional, Bemelman, W, additional, Neefjes-Borst, A, additional, Mookhoek, A, additional, Stoker, J, additional, D'Haens, G, additional, and Gecse, K, additional
- Published
- 2024
- Full Text
- View/download PDF
10. Yield of Adding chest CT to Abdominal CT to Detect COVID-19 in Patients Presenting With Acute Gastrointestinal Symptoms (SCOUT-3): Multicenter Study
- Author
-
Borgstein, A.B.J., Scheijmans, J.C.G., Puylaert, C.A.J., Keywani, K., Lobatto, M.E., Orsini, R.G., van Rees Veillinga, T., van Rossen, J., Scheerder, M.J., Voermans, R.P., Han, A.X., Russell, C.A., Prins, J.M., Gietema, H.A., Stoker, J, Boermeester, M.A., Gisbertz, S.S., and Besselink, M.G.
- Published
- 2022
- Full Text
- View/download PDF
11. [18F]FDG-PET/CT-based risk stratification in women with locally advanced uterine cervical cancer.
- Author
-
Adam, J.A., Poel, E., van Eck Smit, B.L.F., Mom, C.H., Stalpers, L.J.A., Laan, J.J., Kidd, E., Stoker, J., and Bipat, S.
- Subjects
CERVICAL cancer ,POSITRON emission tomography computed tomography - Abstract
Background: [
18 F]FDG-PET/CT is used for staging and treatment planning in patients with locally advanced cervical cancer (LACC). We studied if a PET-based prediction model could provide additional risk stratification beyond International Federation of Gynaecology and Obstetrics (FIGO) staging in our population with LACC to aid treatment decision making. Methods: In total, 183 patients with LACC treated with chemoradiation between 2013 and 2018 were included. Patients were treated according to FIGO 2009 and retrospectively reclassified according to FIGO 2018 staging system. After validation of an existing PET-based prediction model, the predicted recurrent free survival (RFS), disease specific survival (DSS) and overall survival (OS) at 1, 3, and 5 years, based on metabolic tumor volume (MTV), maximum standardized uptake value (SUVmax ) and highest level of [18 F]FDG-positive node was calculated. Then the observed survival was compared to the predicted survival. An area under the curve (AUC) close to or higher than 0.7 was considered adequate for accurate prediction. The Youden (J) index defined survival chance cutoff values for low and high risk groups. Results: All AUC values for the comparison between predicted and observed outcomes were > 0.7 except for 5-year RFS and for 5-year OS which were close to 0.7 (0.684 and 0.650 respectively). Cutoff values for low and high risk survival chance were 0.44 for the 3-year RFS and 0.47 for the 5-year OS. The FIGO 2009 system could not differentiate between the risk profiles. After reclassification according to FIGO 2018, all patients with stage IIIC2 and IVB fell in the high risk and almost all patients with stages IB2-IIIB and IVA in the low risk group. In patients with stage IIIC1 disease the FIGO stage cannot discriminate between the risk profiles. Conclusions: Low and high risk patients with LACC can be identified with the PET-based prediction model. In particular patients with stage IIIC1 need additional risk stratification besides the FIGO 2018 staging. The Kidd model could be a useful tool to aid treatment decision making in these patients. Our results also support the choice of [18 F]FDG-PET/CT imaging in patients with LACC. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
12. Correction to: The awareness of radiologists for the presence of lateral lymph nodes in patients with locally advanced rectal cancer: a single-centre, retrospective cohort study
- Author
-
Sluckin, T. C., Rooker, Y. F. L., Kol, S. Q., Hazen, S. J. A., Tuynman, J. B., Stoker, J., Tanis, P. J., Horsthuis, K., and Kusters, M.
- Published
- 2022
- Full Text
- View/download PDF
13. 656 Food insecurity screening: a 2-year cystic fibrosis clinic quality improvement initiative
- Author
-
Burbidge, K., primary, DeLeon, N., additional, Marker, A., additional, Stoker, J., additional, and McDonald, C., additional
- Published
- 2023
- Full Text
- View/download PDF
14. 450 Identification of lowhand grip strength in children with cystic fibrosis: A quality improvement opportunity
- Author
-
McDonald, C., primary, Stoker, J., additional, and Usher, A., additional
- Published
- 2023
- Full Text
- View/download PDF
15. Simultaneous assessment of colon motility in children with functional constipation by cine-MRI and colonic manometry: a feasibility study
- Author
-
Vriesman, M. H., de Jonge, C. S., Kuizenga-Wessel, S., Adler, B., Menys, A., Nederveen, A. J., Stoker, J., Benninga, M. A., and Di Lorenzo, C.
- Published
- 2021
- Full Text
- View/download PDF
16. The impact and challenges of implementing CTCA according to the 2019 ESC guidelines on chronic coronary syndromes: a survey and projection of CTCA services in the Netherlands
- Author
-
van den Boogert, T. P. W., Claessen, B. E. P. M., Boekholdt, S. M., Leiner, T., Vliegenthart, R., Schuiling, S. F., Timmer, J. R., Bekkers, S. C. A. M., Voskuil, M., Siebelink, H. J., van Es, W., Lamb, H. J., Prokop, M., Damman, P., Stoker, J., Willems, H. C., Henriques, J. P., and Planken, R. N.
- Published
- 2021
- Full Text
- View/download PDF
17. The effectiveness of immediate versus delayed tubal flushing with oil-based contrast in women with unexplained infertility (H2Oil-timing study):study protocol of a randomized controlled trial
- Author
-
Kamphuis, D., Rosielle, K., van Welie, N., Roest, I., van Dongen, A. J. C. M., Brinkhuis, E. A., Bourdrez, P., Mozes, A., Verhoeve, H. R., van der Ham, D. P., Vrouenraets, F. P. J. M., Risseeuw, J. J., van de Laar, T., Janse, F., den Hartog, J. E., de Hundt, M., Hooker, A. B., Huppelschoten, A. G., Pieterse, Q. D., Bongers, M. Y., Stoker, J., Koks, C. A. M., Lambalk, C. B., Hemingway, A., Li, W., Mol, B. W. J., Dreyer, K., Mijatovic, V., Radiology and Nuclear Medicine, CCA - Imaging and biomarkers, AGEM - Amsterdam Gastroenterology Endocrinology Metabolism, Obstetrics and gynaecology, Amsterdam Reproduction & Development (AR&D), and ACS - Atherosclerosis & ischemic syndromes
- Subjects
Fallopian tubes ,HYSTEROSALPINGOGRAPHY ,Obstetrics and Gynecology ,Tubal flushing ,General Medicine ,LIPIODOL ,Hysterosalpingography (HSG) ,Oil-based contrast medium ,Reproductive Medicine ,Fertility work-up ,Pregnancy ,Randomized controlled trial ,Infertility ,Live birth ,Cost-effectiveness - Abstract
Background In women with unexplained infertility, tubal flushing with oil-based contrast during hysterosalpingography leads to significantly more live births as compared to tubal flushing with water-based contrast during hysterosalpingography. However, it is unknown whether incorporating tubal flushing with oil-based contrast in the initial fertility work-up results to a reduced time to conception leading to live birth when compared to delayed tubal flushing that is performed six months after the initial fertility work-up. We also aim to evaluate the effectiveness of tubal flushing with oil-based contrast during hysterosalpingography versus no tubal flushing in the first six months of the study. Methods This study will be an investigator-initiated, open-label, international, multicenter, randomized controlled trial with a planned economic analysis alongside the study. Infertile women between 18 and 39 years of age, who have an ovulatory cycle, who are at low risk for tubal pathology and have been advised expectant management for at least six months (based on the Hunault prediction score) will be included in this study. Eligible women will be randomly allocated (1:1) to immediate tubal flushing (intervention) versus delayed tubal flushing (control group) by using web-based block randomization stratified per study center. The primary outcome is time to conception leading to live birth with conception within twelve months after randomization. We assess the cumulative conception rate at six and twelve months as two co-primary outcomes. Secondary outcomes include ongoing pregnancy rate, live birth rate, miscarriage rate, ectopic pregnancy rate, number of complications, procedural pain score and cost-effectiveness. To demonstrate or refute a shorter time to pregnancy of three months with a power of 90%, a sample size of 554 women is calculated. Discussion The H2Oil-timing study will provide insight into whether tubal flushing with oil-based contrast during hysterosalpingography should be incorporated in the initial fertility work-up in women with unexplained infertility as a therapeutic procedure. If this multicenter RCT shows that tubal flushing with oil-based contrast incorporated in the initial fertility work-up reduces time to conception and is a cost-effective strategy, the results may lead to adjustments of (inter)national guidelines and change clinical practice. Trial registration number The study was retrospectively registered in International Clinical Trials Registry Platform (Main ID: EUCTR2018-004153-24-NL).
- Published
- 2023
18. Precision assessment of bowel motion quantification using 3D cine-MRI for radiotherapy.
- Author
-
Barten, D L J, van Kesteren, Z, Laan, J J, Dassen, M G, Westerveld, G H, Pieters, B R, de Jonge, C S, Stoker, J, and Bel, A
- Subjects
MOTION ,GYNECOLOGIC cancer ,VECTOR fields ,IMAGE registration ,RADIOTHERAPY ,CANCER patients - Abstract
Objective. The bowel is an important organ at risk for toxicity during pelvic and abdominal radiotherapy. Identifying regions of high and low bowel motion with MRI during radiotherapy may help to understand the development of bowel toxicity, but the acquisition time of MRI is rather long. The aim of this study is to retrospectively evaluate the precision of bowel motion quantification and to estimate the minimum MRI acquisition time. Approach. We included 22 gynaecologic cancer patients receiving definitive radiotherapy with curative intent. The 10 min pre-treatment 3D cine-MRI scan consisted of 160 dynamics with an acquisition time of 3.7 s per volume. Deformable registration of consecutive images generated 159 deformation vector fields (DVFs). We defined two motion metrics, the 50th percentile vector lengths (VL50) of the complete set of DVFs was used to measure median bowel motion. The 95th percentile vector lengths (VL95) was used to quantify high motion of the bowel. The precision of these metrics was assessed by calculating their variation (interquartile range) in three different time frames, defined as subsets of 40, 80, and 120 consecutive images, corresponding to acquisition times of 2.5, 5.0, and 7.5 min, respectively. Main results. For the full 10 min scan, the minimum motion per frame of 50% of the bowel volume (M50%) ranged from 0.6–3.5 mm for the VL50 motion metric and 2.3–9.0 mm for the VL95 motion metric, across all patients. At 7.5 min scan time, the variation in M50% was less than 0.5 mm in 100% (VL50) and 95% (VL95) of the subsets. A scan time of 5.0 and 2.5 min achieved a variation within 0.5 mm in 95.2%/81% and 85.7%/57.1% of the subsets, respectively. Significance. Our 3D cine-MRI technique quantifies bowel loop motion with 95%–100% confidence with a precision of 0.5 mm variation or less, using a 7.5 min scan time. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
19. O-192 Does tubal flushing by hysterosalpingo-foam sonography and hysterosalpingography affect tubal patency? Results from a randomized clinical trial
- Author
-
Kamphuis, D, primary, Van Welie, N, additional, Van Hooff, M, additional, Verhoeve, H, additional, De Bruin, J P, additional, Mol, F, additional, Van Baal, M, additional, Van de Laar, B, additional, Lambalk, C, additional, Stoker, J, additional, Van Wely, M, additional, Bossuyt, P, additional, Mol, B, additional, Dreyer, K, additional, and Mijatovic, V, additional
- Published
- 2023
- Full Text
- View/download PDF
20. P296 MAGNIFI-CD index is appropriate for treatment monitoring in perianal Crohn’s Disease
- Author
-
Beek, K, primary, Mulders, L, additional, Tielbeek, J, additional, Horsthuis, K, additional, Buskens, C, additional, D'Haens, G, additional, Gecse, K, additional, and Stoker, J, additional
- Published
- 2023
- Full Text
- View/download PDF
21. P355 Motility in small bowel strictures in Crohn’s Disease measured with cine-MRI
- Author
-
Beek, K, primary, de Jonge, C S, additional, van Rijn, K, additional, de Voogd, F A E, additional, Buskens, C J, additional, D'Haens, G, additional, Gecse, K B, additional, and Stoker, J, additional
- Published
- 2023
- Full Text
- View/download PDF
22. Clinical Added Value of Gadoxetic Acid Enhanced Liver MRI in Patients Scheduled for Local Therapy of Colorectal Liver Metastases Based on CT Imaging (CAMINO)
- Author
-
Görgec, B., primary, Hansen, I., additional, Hartgrink, H.H., additional, Grünhagen, D., additional, Kok, N., additional, Kuhlmann, K., additional, Swijnenburg, R.-J., additional, Fretland, A.A., additional, Verhoef, K., additional, Besselink, M.G., additional, and Stoker, J., additional
- Published
- 2023
- Full Text
- View/download PDF
23. Additional file 2 of The effectiveness of immediate versus delayed tubal flushing with oil-based contrast in women with unexplained infertility (H2Oil-timing study): study protocol of a randomized controlled trial
- Author
-
Kamphuis, D., Rosielle, K., van Welie, N., Roest, I., van Dongen, A. J.C.M., Brinkhuis, E. A., Bourdrez, P., Mozes, A., Verhoeve, H. R., van der Ham, D. P., Vrouenraets, F. P.J.M., Risseeuw, J. J., van de Laar, T., Janse, F., den Hartog, J. E., de Hundt, M., Hooker, A. B., Huppelschoten, A. G., Pieterse, Q. D., Bongers, M. Y., Stoker, J., Koks, C. A.M., Lambalk, C. B., Hemingway, A., Li, W., Mol, B. W.J., Dreyer, K., and Mijatovic, V.
- Abstract
Supplementary Material 2: List of participating sites.
- Published
- 2023
- Full Text
- View/download PDF
24. Additional file 1 of The effectiveness of immediate versus delayed tubal flushing with oil-based contrast in women with unexplained infertility (H2Oil-timing study): study protocol of a randomized controlled trial
- Author
-
Kamphuis, D., Rosielle, K., van Welie, N., Roest, I., van Dongen, A. J.C.M., Brinkhuis, E. A., Bourdrez, P., Mozes, A., Verhoeve, H. R., van der Ham, D. P., Vrouenraets, F. P.J.M., Risseeuw, J. J., van de Laar, T., Janse, F., den Hartog, J. E., de Hundt, M., Hooker, A. B., Huppelschoten, A. G., Pieterse, Q. D., Bongers, M. Y., Stoker, J., Koks, C. A.M., Lambalk, C. B., Hemingway, A., Li, W., Mol, B. W.J., Dreyer, K., and Mijatovic, V.
- Abstract
Supplementary Material 1: Trial registration data set.
- Published
- 2023
- Full Text
- View/download PDF
25. Correction to:The awareness of radiologists for the presence of lateral lymph nodes in patients with locally advanced rectal cancer: a single-centre, retrospective cohort study (European Radiology, (2022), 32, 10, (6637-6645), 10.1007/s00330-022-08840-1)
- Author
-
Sluckin, T. C., Rooker, Y. F. L., Kol, S. Q., Hazen, S. J. A., Tuynman, J. B., Stoker, J., Tanis, P. J., Horsthuis, K., and Kusters, M.
- Abstract
The original version of this article, published on 18May 2022, unfortunately contained some mistakes. The affiliations were incorrectly rearranged during the typesetting stage. They are now corrected in this paper. The original article has been corrected.
- Published
- 2022
26. Correction to: The awareness of radiologists for the presence of lateral lymph nodes in patients with locally advanced rectal cancer: a single-centre, retrospective cohort study (European Radiology, (2022), 32, 10, (6637-6645), 10.1007/s00330-022-08840-1)
- Author
-
Sluckin, T. C., Rooker, Y. F. L., Kol, S. Q., Hazen, S. J. A., Tuynman, J. B., Stoker, J., Tanis, P. J., Horsthuis, K., Kusters, M., Surgery, Cancer Center Amsterdam, Radiology and nuclear medicine, CCA - Cancer Treatment and quality of life, CCA - Imaging and biomarkers, Amsterdam Gastroenterology Endocrinology Metabolism, Radiology and Nuclear Medicine, and CCA - Cancer Treatment and Quality of Life
- Abstract
The original version of this article, published on 18May 2022, unfortunately contained some mistakes. The affiliations were incorrectly rearranged during the typesetting stage. They are now corrected in this paper. The original article has been corrected.
- Published
- 2022
27. CT-COLONOGRAPHY IN FECAL IMMUNOCHEMICAL TEST POSITIVE PATIENTS IN A COLORECTAL CANCER SCREENING PROGRAM – YIELD AND INCIDENCE OF INTERVAL CARCINOMAS
- Author
-
Moen, S., additional, Marijnissen, F.E., additional, Terhaar Sive Droste, J.S., additional, de Vos tot Nederveen Cappel, W.H., additional, Spanier, M.B.W., additional, Huisman, J.F., additional, Dekker, E., additional, Stoker, J., additional, Kuipers, E.J., additional, Thomeer, M.G.J., additional, and Spaander, M.C.W., additional
- Published
- 2022
- Full Text
- View/download PDF
28. Additional file 2 of Oil-based versus water-based contrast media for hysterosalpingography in infertile women of advanced age, with ovulation disorders or a high risk for tubal pathology: study protocol of a randomized controlled trial (H2Oil2 study)
- Author
-
Rosielle, K., Kamphuis, D., van Welie, N., Roest, I., Mozes, A., van Santbrink, E. J. P., van de Laar, T., Hooker, A. B., Huppelschoten, A. G., Li, W., Bongers, M. Y., Stoker, J., van Wely, M., Koks, C., Lambalk, C. B., Hemingway, A., Mol, B. W. J., Dreyer, K., and Mijatovic, V.
- Abstract
Additional file 2. List of currently participating centres of H2Oil2 as per March 1st 2022 and their local head investigators
- Published
- 2022
- Full Text
- View/download PDF
29. Additional file 1 of Oil-based versus water-based contrast media for hysterosalpingography in infertile women of advanced age, with ovulation disorders or a high risk for tubal pathology: study protocol of a randomized controlled trial (H2Oil2 study)
- Author
-
Rosielle, K., Kamphuis, D., van Welie, N., Roest, I., Mozes, A., van Santbrink, E. J. P., van de Laar, T., Hooker, A. B., Huppelschoten, A. G., Li, W., Bongers, M. Y., Stoker, J., van Wely, M., Koks, C., Lambalk, C. B., Hemingway, A., Mol, B. W. J., Dreyer, K., and Mijatovic, V.
- Abstract
Additional file 1. Table S1: Description of data: WHO Trial registration data set
- Published
- 2022
- Full Text
- View/download PDF
30. Clinical Added Value of MRI to CT in Patients Scheduled for Local Therapy of Colorectal Liver Metastases (CAMINO): An International Multicenter Prospective Diagnostic Accuracy Study
- Author
-
Gorgec, B., primary, Hansen, I.S., additional, Kemmerich, G., additional, Syversveen, T., additional, Hilal, M Abu, additional, Bosscha, K., additional, Burgmans, M.C., additional, Edwin, B., additional, D'Hondt, M., additional, Gobardhan, P., additional, Gielkens, H., additional, Hartgrink, H.H., additional, Marsman, H.A., additional, Morone, M., additional, Kint, P.A.M., additional, Kok, N., additional, Kuhlmann, K., additional, Lips, D.J., additional, Peringa, J., additional, Willemssen, F., additional, Fretland, A.A., additional, Swijnenburg, R.J., additional, Verhoef, C., additional, Besselink, M.G., additional, and Stoker, J., additional
- Published
- 2022
- Full Text
- View/download PDF
31. Interobserver Variability in Morphologic Tumor Response Assessment Following Systemic Therapy in Patients with Initially Unresectable Colorectal Liver Metastases
- Author
-
Wesdorp, N.J., primary, Kemna, R., additional, Waesberghe, J.-H.T. van, additional, Nota, I.M., additional, Struik, F., additional, Abdennabi, I. Oulad, additional, Phoa, S.S., additional, van Dieren, S., additional, Swijnenburg, R.-J., additional, Punt, C.J., additional, Huiskens, J., additional, Stoker, J., additional, and Kazemier, G., additional
- Published
- 2022
- Full Text
- View/download PDF
32. DOP30 Long-term outcomes of Crohn’s perianal fistulas treatment: anti-TNF with surgical closure versus anti-TNF alone (PISA-II) - A patient preference RCT
- Author
-
Meima - van Praag MD, E, primary, Stoker, J, additional, D’Haens, G, additional, Gecse, K, additional, Dijkgraaf, M, additional, Bemelman, W, additional, and Buskens, C, additional
- Published
- 2022
- Full Text
- View/download PDF
33. Clinical added value of MRI to CT in patients scheduled for local therapy of colorectal liver metastases (CAMINO)
- Author
-
Görgec, B., Hansen, I., Kemmerich, G., Syversveen, T., Abu Hilal, M., Belt, E. J. T., Bisschops, R. H. C., Bollen, T. L., Bosscha, K., Burgmans, M. C., Cappendijk, V., de Boer, M. T., D’Hondt, M., Edwin, B., Gielkens, H., Grünhagen, D. J., Gillardin, P., Gobardhan, P. D., Hartgrink, H. H., Horsthuis, K., Kok, N. F. M., Kint, P. A. M., Kruimer, J. W. H., Leclercq, W. K. G., Lips, D. J., Lutin, B., Maas, M., Marsman, H. A., Morone, M., Pennings, J. P., Peringa, J., te Riele, W. W., Vermaas, M., Wicherts, D., Willemssen, F. E. J. A., Zonderhuis, B. M., Bossuyt, P. M. M., Swijnenburg, R. J., Fretland, A., Verhoef, C., Besselink, M. G., Stoker, J., Bnà, C., de Meyere, C., Draaisma, W. A., Gerhards, M. F., Imani, F., Kuhlmann, K. F. D., Liem, M. S. L., Meyer, Y., Surgery, Radiology & Nuclear Medicine, Graduate School, Radiology and Nuclear Medicine, AMS - Rehabilitation & Development, AMS - Sports, Amsterdam Gastroenterology Endocrinology Metabolism, Epidemiology and Data Science, APH - Methodology, APH - Personalized Medicine, CCA - Imaging and biomarkers, CCA - Cancer Treatment and Quality of Life, Radiology and nuclear medicine, Pathology, Obstetrics and gynaecology, CCA - Cancer Treatment and quality of life, AGEM - Re-generation and cancer of the digestive system, and VU University medical center
- Subjects
Gadolinium DTPA ,Cancer Research ,Colorectal cancer ,Gadoxetic acid ,Contrast Media ,Diagnostic accuracy ,Multimodal Imaging ,Liver MRI ,Study Protocol ,Liver metastases ,Prospective Studies ,FDG-PET ,RC254-282 ,OUTCOMES ,medicine.diagnostic_test ,Minimal clinically important difference ,Liver Neoplasms ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Magnetic Resonance Imaging ,Oncology ,SURVIVAL ,Radiology ,Colorectal Neoplasms ,Life Sciences & Biomedicine ,medicine.drug ,Adult ,medicine.medical_specialty ,STRATEGIES ,HEPATIC RESECTION ,SDG 3 - Good Health and Well-being ,Genetics ,medicine ,Humans ,In patient ,CANCER PATIENTS ,RADIOFREQUENCY ABLATION ,Liver surgery ,RECURRENCE ,Protocol (science) ,Science & Technology ,business.industry ,Abdominal CT scan ,Magnetic resonance imaging ,Diffusion weighted imaging ,PERFORMANCE ,medicine.disease ,Thermal ablation ,Colorectal liver metastases ,CONTRAST-ENHANCED CT ,Tomography, X-Ray Computed ,business ,Diffusion MRI - Abstract
Background Abdominal computed tomography (CT) is the standard imaging method for patients with suspected colorectal liver metastases (CRLM) in the diagnostic workup for surgery or thermal ablation. Diffusion-weighted and gadoxetic-acid-enhanced magnetic resonance imaging (MRI) of the liver is increasingly used to improve the detection rate and characterization of liver lesions. MRI is superior in detection and characterization of CRLM as compared to CT. However, it is unknown how MRI actually impacts patient management. The primary aim of the CAMINO study is to evaluate whether MRI has sufficient clinical added value to be routinely added to CT in the staging of CRLM. The secondary objective is to identify subgroups who benefit the most from additional MRI. Methods In this international multicentre prospective incremental diagnostic accuracy study, 298 patients with primary or recurrent CRLM scheduled for curative liver resection or thermal ablation based on CT staging will be enrolled from 17 centres across the Netherlands, Belgium, Norway, and Italy. All study participants will undergo CT and diffusion-weighted and gadoxetic-acid enhanced MRI prior to local therapy. The local multidisciplinary team will provide two local therapy plans: first, based on CT-staging and second, based on both CT and MRI. The primary outcome measure is the proportion of clinically significant CRLM (CS-CRLM) detected by MRI not visible on CT. CS-CRLM are defined as liver lesions leading to a change in local therapeutical management. If MRI detects new CRLM in segments which would have been resected in the original operative plan, these are not considered CS-CRLM. It is hypothesized that MRI will lead to the detection of CS-CRLM in ≥10% of patients which is considered the minimal clinically important difference. Furthermore, a prediction model will be developed using multivariable logistic regression modelling to evaluate the predictive value of patient, tumor and procedural variables on finding CS-CRLM on MRI. Discussion The CAMINO study will clarify the clinical added value of MRI to CT in patients with CRLM scheduled for local therapy. This study will provide the evidence required for the implementation of additional MRI in the routine work-up of patients with primary and recurrent CRLM for local therapy. Trial registration The CAMINO study was registered in the Netherlands National Trial Register under number NL8039 on September 20th 2019.
- Published
- 2021
34. Prognostic and predictive value of total tumor volume in patients with colorectal liver metastases.
- Author
-
Zeeuw, M., Wesdorp, N., Ali, M., Voigt, K., Starmans, M., Roor, J., Waesberghe, J.-H. van, van den Bergh, J., Nota, I., Moos, S., Stoker, J., Grunhagen, D., Swijnenburg, R.-J., Punt, C., Huiskens, J., Verhoef, K., and Kazemier, G.
- Published
- 2024
- Full Text
- View/download PDF
35. Advancing total tumor volume estimation in colorectal liver metastases: development and evaluation of a self-learning auto-segmentation model.
- Author
-
Zeeuw, M., Bereska, J., Wagenaar, L., van der Meulen, D., Wesdorp, N., Janssen, B., Besselink, M., Marquering, H., Waesberghe, J.-H. van, van den Bergh, J., Nota, I., Moos, S., Jenssen, H., Huiskens, J., Swijnenburg, R.-J., Punt, C., Stoker, J., Fretland, A., Kazemier, G., and Verpalen, I.
- Published
- 2024
- Full Text
- View/download PDF
36. Identifying genetic mutation status in patients with colorectal liver metastases using radiomics based machine learning models.
- Author
-
Wesdorp, N.J., Zeeuw, J.M., van der Meulen, D., Erve, I. van 't, Bodalal, Z., Roor, J., van Waesberghe, J.H.T., Moos, S., van den Bergh, J., Nota, I., van Dieren, S., Stoker, J., Meijer, G.A., Swijnenburg, R.-J., Punt, C.J., Huiskens, J., Beets-Tan, R., Fijneman, R.J.A., Marquering, H.A., and Kazemier, G.
- Published
- 2024
- Full Text
- View/download PDF
37. Surgical innovations in the multidisciplinary treatment of Crohn’s disease
- Author
-
Meima-van Praag, E.M., Bemelman, W.A., Stoker, J., Buskens, C.J., Gecse, K.B., and Faculteit der Geneeskunde
- Abstract
This thesis focuses on the surgical treatment of patients with Crohn’s disease. Part I describes and evaluates multiple treatment methods of perianal fistulas in patients with Crohn’s disease, especially the ligation of the intersphincteric fistula tract procedure and the advancement flap procedure. Multiple clinical outcome parameters as well as radiological healing after these surgical closure procedures were evaluated. Furthermore, outcome parameters after short-term anti-TNF therapy combined with surgical closure were directly compared to medical therapy only as treatment of Crohn’s perianal fistulas in the PISA-II trial; a patient preference randomised controlled trial. Both 18 month and long-term outcomes are described. Also, fistula characteristics on MRI after surgical closure and the relationship between those characteristics to patients’ clinical outcomes were evaluated, and it was evaluated whether certain MRI features could be used to predict clinical outcome in patients after surgical closure. Part II of this thesis focuses on multiple (new) surgical treatment strategies for different problems of Crohn’s disease. Important dilemmas for medically refractory or complex Crohn’s disease are discussed. Furthermore, a novel treatment method using the Semiflex Dome System, a catheter set for vacuum therapy of perianal abscesses and fistulas is described. Lastly, in order to make management of the complex problem of the chronically failing pouch more comprehensible and make results between different centres more comparable, a new classification system for the surgical treatment of the chronically failing ileo-anal pouch is suggested in this thesis.
- Published
- 2023
38. Advances in CT pulmonary angiography for pulmonary embolism
- Author
-
Beenen, L.F.M., Middeldorp, S., Stoker, J., and Faculteit der Geneeskunde
- Abstract
In this thesis the possibilities of improving the clinical workflow and risk assessment of patients with the suspicion of a pulmonary embolism in general, and in specific populations and circumstances have been explored. With computed tomography pulmonary angiography (CTPA) not only the presence of pulmonary emboli can be diagnosed, but also risk estimation can be established. Part I of this thesis describes the development of a new diagnostic management strategy for patients with the suspicion of a pulmonary embolism, by combining three Wells criteria (haemoptysis, signs of deep vein thrombosis and ‘pulmonary embolism most likely’) with the D-dimer test result. Use of this YEARS algorithm resulted in an absolute 14% decrease of CTPA examinations in all ages and across several subgroups. In Part II we explored in patients with proven pulmonary embolism the additional value of CTPA on risk assessment and prognosis. It appeared that only an enlarged pulmonary trunk diameter was associated with an increased risk of mortality. Additionally, concomitant disease on the baseline CTPA impacts mortality in a severity dependent manner. Worse outcomes are observed in patients who are overweight or underweight. In Part III, the interaction between COVID-19 and pulmonary embolism and deep vein thrombosis is discussed. The risk for thrombotic disease in COVID-19 is very high, particularly in ICU patients. ICU patients also show severely diminished perfusion on dual energy CTPA, consistent with diffuse pulmonary microcirculatory dysfunction, which could explain the occurrence of severe and persistent respiratory failure.
- Published
- 2022
39. MRI for gastrointestinal diseases: Advances in assessment of small bowel motility and perianal Crohn’s disease
- Author
-
van Rijn, K.L., Stoker, J., Löwenberg, M., de Jonge, C.S., and Faculteit der Geneeskunde
- Abstract
Magnetic Resonance Imaging (MRI) is a frequently used imaging technique for several gastrointestinal diseases. The research in this thesis focuses on advances in the use of cine-MRI for small bowel motility disorders and MRI for perianal Crohn’s disease. Cine-MRI has been increasingly used to investigate small bowel motility disorders. In this thesis, the robustness of quantified small bowel motility measurements in different populations is evaluated. Furthermore, the use of cine-MRI to gain insight in small bowel motility patterns in the severe motility disorder chronic intestinal pseudo-obstruction (CIPO) is investigated. For Crohn’s perianal fistulas, MRI is the recommended imaging technique to evaluate fistula activity and response to treatment. Several MRI scores have been developed to evaluate treatment response and fistula healing. In this thesis, different MRI scores are evaluated in patients receiving medical and surgical treatment. Furthermore the role of MRI to predict long-term treatment outcomes is investigated and fistula healing at MRI is compared between different treatments.
- Published
- 2022
40. External validation of the MAGNIFI-CD index in patients with complex perianal fistulising Crohn's disease.
- Author
-
Beek KJ, Mulders LGM, van Rijn KL, Horsthuis K, Tielbeek JAW, Buskens CJ, D'Haens GR, Gecse KB, and Stoker J
- Abstract
Background: There is an increasing need for objective treatment monitoring in perianal fistulising Crohn's disease (pfCD). Therefore, the magnetic resonance novel index for fistula imaging in CD (MAGNIFI-CD) index has been designed and internally validated on the ADMIRE-CD trial cohort. The aim of this study was to externally validate the MAGNIFI-CD index to monitor response to medical and surgical treatment regimens in pfCD., Methods: A retrospective longitudinal cohort was established of consecutive patients with complex pfCD treated with surgical and/or medical therapy and a baseline and follow-up MRI between January 2007 and May 2021. The MAGNIFI-CD index was scored by two independent, abdominal radiologists blinded for time points and clinical outcomes. Responsiveness, reliability, and test accuracy regarding clinically important improvement were assessed. Cut-offs for response and remission were selected classified on fistula drainage assessment and physician global assessment., Results: A total of 65 patients (51% female, median age 32 years) were included. A clinically relevant responsiveness of the MAGNIFI-CD was shown, with a significant decrease in clinical remitters and responders with a median MAGNIFI-CD of 18.0 [7.5-20.0] to 9.0 [0.8-16.0] (p < 0.001) and non-significant change in non-responders with a median MAGNIFI-CD of 20.0 [12.0-23.0] to 18.0 [13.0-21.0] (p = 0.22). There was an 'almost perfect' interobserver agreement (ICC = 0.87; 95% CI 0.80-0.92) for the MAGNIFI-CD index. An optimal cut-off value was defined as a decrease of 2 points for clinical response, and a MAGNIFI-CD ≤ 6 for remission at follow-up MRI., Conclusion: The MAGNIFI-CD index is a responsive and reliable MRI scoring instrument for treatment monitoring in perianal fistulising Crohn's disease., Clinical Relevance Statement: The MAGNIFI-CD index is a well-structured, responsive scoring instrument to assess fistula severity and activity that allows quantitative detection of changes in therapy response in patients with perianal fistulising Crohn's disease, thereby facilitating endpoints in clinical trials., Key Points: Well-defined cut-offs for response and remission are needed for objective treatment monitoring of perianal fistulising Crohn's disease (pfCD). Cut-off values for remission and for response at 6 months follow-up were defined. Interobserver agreement was good. The MAGNIFI-CD index is responsive and reliable for treatment monitoring and is suitable for use in clinical trials., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
41. Quantitative Analysis of Small Intestinal Motility in 3D Cine-MRI Using Centerline-Aware Motion Estimation.
- Author
-
van Harten LD, de Jonge CS, Struik F, Stoker J, and Išgum I
- Abstract
Background: Currently available tools for noninvasive motility quantification of the small intestine are limited to dynamic 2D MRI scans, which are limited in their ability to differentiate between types of intestinal motility., Purpose: To develop a method for quantification and characterization of small intestinal motility in 3D, capable of differentiating motile, non-motile and peristaltic motion patterns., Study Type: Prospective., Subjects: Fourteen healthy volunteers (127 small intestinal segments) and 10 patients with Crohn's disease (87 small intestinal segments)., Field Strength/sequence: 3.0 T, 3D balanced fast field echo sequence, 1 volume per second., Assessment: Using deformable image registration between subsequent volumes, the local velocity within the intestinal lumen was quantified. Average velocity and average absolute velocity along intestinal segments were used with linear classifiers to differentiate motile from non-motile intestines, as well as erratic motility from peristalsis. The mean absolute velocity of small intestinal content was compared between healthy volunteers and Crohn's disease patients, and the discriminative power of the proposed motility metrics for detecting motility and peristalsis was determined. The consensus of two observers was used as referenced standard., Statistical Tests: Student's t-test to assess differences between groups; area under the receiver operating characteristic curve (AUC) to assess discriminative ability. P < 0.001 was considered significant., Results: A significant difference in the absolute velocity of intestinal content between Crohn's patients and healthy volunteers was observed (median [IQR] 1.06 [0.61, 1.56] mm/s vs. 1.84 [1.37, 2.43] mm/s), which was consistent with manual reference annotations of motile activity. The proposed method had a strong discriminative performance for detecting non-motile intestines (AUC 0.97) and discernible peristalsis (AUC 0.81)., Data Conclusion: Analysis of 3D cine-MRI using centerline-aware motion estimation has the potential to allow noninvasive characterization of small intestinal motility and peristaltic motion in 3D., Evidence Level: 3 TECHNICAL EFFICACY: Stage 2., (© 2024 The Author(s). Journal of Magnetic Resonance Imaging published by Wiley Periodicals LLC on behalf of International Society for Magnetic Resonance in Medicine.)
- Published
- 2024
- Full Text
- View/download PDF
42. The effect of prior hysterosalpingo-foam sonography or hysterosalpingography on tubal patency: a secondary analysis of a randomized controlled trial.
- Author
-
Kamphuis D, van Welie N, van Rijswijk J, van Hooff MHA, de Bruin JP, Verhoeve HR, Mol F, van Baal WM, Lambalk CB, Stoker J, van Wely M, Bossuyt PMM, Mol BWJ, Dreyer K, and Mijatovic V
- Abstract
Study Question: Does hysterosalpingo-foam sonography (HyFoSy) prior to hysterosalpingography (HSG) or HSG prior to HyFoSy affect visible tubal patency when compared HSG or HyFoSy alone?, Summary Answer: Undergoing either HyFoSy or HSG prior to tubal patency testing by the alternative method does not demonstrate a significant difference in visible tubal patency when compared to HyFoSy or HSG alone., What Is Known Already: HyFoSy and HSG are two commonly used visual tubal patency tests with a high and comparable diagnostic accuracy for evaluating tubal patency. These tests may also improve fertility, although the underlying mechanism is still not fully understood. One of the hypotheses points to a dislodgment of mucus plugs that may have disrupted the patency of the Fallopian tubes., Study Design, Size, Duration: This is a secondary analysis of the randomized controlled FOAM study, in which women underwent tubal patency testing by HyFoSy and HSG, randomized for order of the procedure. Participants either had HyFoSy first and then HSG, or vice versa. Here, we evaluate the relative effectiveness of tubal patency testing by HyFoSy or HSG prior to the alternative tubal patency testing method on visible tubal patency, compared to each method alone., Participants/materials, Setting, Methods: Infertile women aged between 18 and 41 years scheduled for tubal patency testing were eligible for participating in the FOAM study. Women with anovulatory cycles, endometriosis, or with a partner with male infertility were excluded. To evaluate the effect HyFoSy on tubal patency, we relied on HSG results by comparing the proportion of women with bilateral tubal patency visible on HSG in those who underwent and who did not undergo HyFoSy prior to their HSG (HyFoSy prior to HSG versus HSG alone). To evaluate the effect of HSG on tubal patency, we relied on HyFoSy results by comparing the proportion of women with bilateral tubal patency visible on HyFoSy in those who underwent and who did not undergo HSG prior to their HyFoSy (HSG prior to HyFoSy versus HyFoSy alone)., Main Results and the Role of Chance: Between May 2015 and January 2019, we randomized 1160 women (576 underwent HyFoSy first followed by HSG, and 584 underwent HSG first followed by HyFoSy). Among the women randomized to HyFoSy prior to HSG, bilateral tubal patency was visible on HSG in 467/537 (87%) women, compared with 472/544 (87%) women who underwent HSG alone (risk difference 0.2%; 95% CI: -3.8% to 4.2%). Among the women randomized to HSG prior to HyFoSy, bilateral tubal patency was visible on HyFoSy in 394/471 (84%) women, compared with 428/486 (88%) women who underwent HyFoSy alone (risk difference -4.4%; 95% CI: -8.8% to 0.0%)., Limitations, Reasons for Caution: The results of this secondary analysis should be interpreted as exploratory and cannot be regarded as definitive evidence. Furthermore, it has to be noted that pregnancy outcomes were not considered in this analysis., Wider Implications of the Findings: Tubal patency testing by either HyFoSy or HSG, prior to the alternative tubal patency testing method does not significantly affect visible tubal patency, when compared to alternative method alone. This suggests that both methods may have comparable abilities to dislodge mucus plugs in the Fallopian tubes., Study Funding/competing Interest(s): The FOAM study was an investigator-initiated study, funded by ZonMw, a Dutch organization for Health Research and Development (project number 837001504). IQ Medical Ventures provided the ExEm®-FOAM kits free of charge. The funders had no role in study design, collection, analysis, or interpretation of the data. H.R.V. reports consultancy fees from Ferring. M.v.W. received a travel grant from Oxford University Press in the role of Deputy Editor for Human Reproduction and participates in a Data Safety and Monitoring Board as an independent methodologist in obstetrics studies in which she has no other role. M.v.W. is coordinating editor of Cochrane Fertility and Gynaecology. B.W.J.M. received an investigator grant from NHMRC (GNT1176437) and research funding from Merck KGaA. B.W.J.M. reports consultancy for Organon and Merck KGaA, and travel support from Merck KGaA. B.W.J.M. reports holding stocks of ObsEva. V.M. received research grants from Guerbet, Merck and Ferring and travel and speaker fees from Guerbet. The other authors do not report conflicts of interest., Trial Registration Number: International Clinical Trials Registry Platform No. NTR4746., (© The Author(s) 2024. Published by Oxford University Press on behalf of European Society of Human Reproduction and Embryology.)
- Published
- 2024
- Full Text
- View/download PDF
43. Reliability of MR Enterography Features for Describing Fibrostenosing Crohn Disease.
- Author
-
Rieder F, Baker ME, Bruining DH, Fidler JL, Ehman EC, Sheedy SP, Heiken JP, Ream JM, Holmes DR 3rd, Inoue A, Mohammadinejad P, Lee YS, Taylor SA, Stoker J, Zou G, Wang Z, Rémillard J, Carter RE, Ottichilo R, Atkinson N, Siddiqui MT, Sunkesula VC, Ma C, Parker CE, Panés J, Rimola J, Jairath V, Feagan BG, and Fletcher JG
- Subjects
- Humans, Female, Male, Retrospective Studies, Adult, Reproducibility of Results, Constriction, Pathologic diagnostic imaging, Middle Aged, Crohn Disease diagnostic imaging, Magnetic Resonance Imaging methods
- Abstract
Background Clinical decision making and drug development for fibrostenosing Crohn disease is constrained by a lack of imaging definitions, scoring conventions, and validated end points. Purpose To assess the reliability of MR enterography features to describe Crohn disease strictures and determine correlation with stricture severity. Materials and Methods A retrospective study of patients with symptomatic terminal ileal Crohn disease strictures who underwent MR enterography at tertiary care centers (Cleveland Clinic: September 2013 to November 2020; Mayo Clinic: February 2008 to March 2019) was conducted by using convenience sampling. In the development phase, blinded and trained radiologists independently evaluated 26 MR enterography features from baseline and follow-up examinations performed more than 6 months apart, with no bowel resection performed between examinations. Follow-up examinations closest to 12 months after baseline were selected. Reliability was assessed using the intraclass correlation coefficient (ICC). In the validation phase, after five features were redefined, reliability was re-estimated in an independent convenience sample using baseline examinations. Multivariable linear regression analysis identified features with at least moderate interrater reliability (ICC ≥0.41) that were independently associated with stricture severity. Results Ninety-nine (mean age, 40 years ± 14 [SD]; 50 male) patients were included in the development group and 51 (mean age, 45 years ± 16 [SD]; 35 female) patients were included in the validation group. In the development group, nine features had at least moderate interrater reliability. One additional feature demonstrated moderate reliability in the validation group. Stricture length (ICC = 0.85 [95% CI: 0.75, 0.91] and 0.91 [95% CI: 0.75, 0.96] in development and validation phase, respectively) and maximal associated small bowel dilation (ICC = 0.74 [95% CI: 0.63, 0.80] and 0.73 [95% CI: 0.58, 0.87] in development and validation group, respectively) had the highest interrater reliability. Stricture length, maximal stricture wall thickness, and maximal associated small bowel dilation were independently (regression coefficients, 0.09-3.97; P < .001) associated with stricture severity. Conclusion MR enterography definitions and scoring conventions for reliably assessing features of Crohn disease strictures were developed and validated, and feature correlation with stricture severity was determined. © RSNA, 2024 Supplemental material is available for this article. See also the article by Rieder and Ma et al in this issue. See also the editorial by Galgano and Summerlin in this issue.
- Published
- 2024
- Full Text
- View/download PDF
44. Prognostic value of total tumor volume in patients with colorectal liver metastases: A secondary analysis of the randomized CAIRO5 trial with external cohort validation.
- Author
-
Michiel Zeeuw J, Wesdorp NJ, Ali M, Bakker AJJ, Voigt KR, Starmans MPA, Roor J, Kemna R, van Waesberghe JHTM, van den Bergh JE, Nota IMGC, Moos SI, van Dieren S, van Amerongen MJ, Bond MJG, Chapelle T, van Dam RM, Engelbrecht MRW, Gerhards MF, van Gulik TM, Hermans JJ, de Jong KP, Klaase JM, Kok NFM, Leclercq WKG, Liem MSL, van Lienden KP, Quintus Molenaar I, Patijn GA, Rijken AM, Ruers TM, de Wilt JHW, Verpalen IM, Stoker J, Grunhagen DJ, Swijnenburg RJ, Punt CJA, Huiskens J, Verhoef C, and Kazemier G
- Subjects
- Humans, Male, Female, Middle Aged, Prognosis, Aged, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Adult, Liver Neoplasms secondary, Liver Neoplasms drug therapy, Liver Neoplasms diagnostic imaging, Colorectal Neoplasms pathology, Colorectal Neoplasms mortality, Tumor Burden, Neoplasm Recurrence, Local pathology
- Abstract
Background: This study aimed to assess the prognostic value of total tumor volume (TTV) for early recurrence (within 6 months) and overall survival (OS) in patients with colorectal liver metastases (CRLM), treated with induction systemic therapy followed by complete local treatment., Methods: Patients with initially unresectable CRLM from the multicenter randomized phase 3 CAIRO5 trial (NCT02162563) who received induction systemic therapy followed by local treatment were included. Baseline TTV and change in TTV as response to systemic therapy were calculated using the CT scan before and the first after systemic treatment, and were assessed for their added prognostic value. The findings were validated in an external cohort of patients treated at a tertiary center., Results: In total, 215 CAIRO5 patients were included. Baseline TTV and absolute change in TTV were significantly associated with early recurrence (P = 0.005 and P = 0.040, respectively) and OS in multivariable analyses (P = 0.024 and P = 0.006, respectively), whereas RECIST1.1 was not prognostic for early recurrence (P = 0.88) and OS (P = 0.35). In the validation cohort (n = 85), baseline TTV and absolute change in TTV remained prognostic for early recurrence (P = 0.041 and P = 0.021, respectively) and OS in multivariable analyses (P < 0.0001 and P = 0.012, respectively), and showed added prognostic value over conventional clinicopathological variables (increase C-statistic, 0.06; 95 % CI, 0.02 to 0.14; P = 0.008)., Conclusion: Total tumor volume is strongly prognostic for early recurrence and OS in patients who underwent complete local treatment of initially unresectable CRLM, both in the CAIRO5 trial and the validation cohort. In contrast, RECIST1.1 did not show prognostic value for neither early recurrence nor OS., Competing Interests: Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: The authors of this manuscript declare relationships with the following companies: C.J.A.P. has an advisory role for Nordic Pharma; SAS Analytics paid for traveling expenses G. Kazemier. This funding is not related to the current research. The remaining authors declare no potential conflicts of interest., (Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
45. Correction: Recurrent disease detection after resection of pancreatic ductal adenocarcinoma using a recurrence-focused surveillance strategy (RADAR-PANC): protocol of an international randomized controlled trial according to the Trials within Cohorts design.
- Author
-
Daamen LA, van Goor IWJM, Groot VP, Andel PCM, Brosens LAA, Busch OR, Cirkel GA, Mohammad NH, Heerkens HD, de Hingh IHJT, Hoogwater F, van Laarhoven HWM, Los M, Meijer GJ, de Meijer VE, Pande R, Roberts KJ, Stoker J, Stommel MWJ, van Tienhoven G, Verdonk RC, Verkooijen HM, Wessels FJ, Wilmink JW, Besselink MG, van Santvoort HC, Intven MPW, and Molenaar IQ
- Published
- 2024
- Full Text
- View/download PDF
46. Hysterosalpingo-foam sonography versus hysterosalpingography during fertility work-up: an economic evaluation alongside a randomized controlled trial.
- Author
-
Kamphuis D, van Eekelen R, van Welie N, Dreyer K, van Rijswijk J, van Hooff MHA, de Bruin JP, Verhoeve HR, Mol F, van Baal WM, Traas MAF, van Peperstraten AM, Manger AP, Gianotten J, de Koning CH, Koning AMH, Bayram N, van der Ham DP, Vrouenraets FPJM, Kalafusova M, van de Laar BIG, Kaijser J, Lambeek AF, Meijer WJ, Broekmans FJM, Valkenburg O, van der Voet LF, van Disseldorp J, Lambers MJ, Tros R, Lambalk CB, Stoker J, van Wely M, Bossuyt PMM, Mol BWJ, and Mijatovic V
- Subjects
- Humans, Female, Adult, Pregnancy, Cost-Benefit Analysis, Pregnancy Rate, Live Birth, Birth Rate, Hysterosalpingography methods, Hysterosalpingography economics, Infertility, Female therapy, Infertility, Female economics, Fallopian Tube Patency Tests methods, Fallopian Tube Patency Tests economics, Ultrasonography economics, Ultrasonography methods
- Abstract
Study Question: What are the costs and effects of tubal patency testing by hysterosalpingo-foam sonography (HyFoSy) compared to hysterosalpingography (HSG) in infertile women during the fertility work-up?, Summary Answer: During the fertility work-up, clinical management based on the test results of HyFoSy leads to slightly lower, though not statistically significant, live birth rates, at lower costs, compared to management based on HSG results., What Is Known Already: Traditionally, tubal patency testing during the fertility work-up is performed by HSG. The FOAM trial, formally a non-inferiority study, showed that management decisions based on the results of HyFoSy resulted in a comparable live birth rate at 12 months compared to HSG (46% versus 47%; difference -1.2%, 95% CI: -3.4% to 1.5%; P = 0.27). Compared to HSG, HyFoSy is associated with significantly less pain, it lacks ionizing radiation and exposure to iodinated contrast medium. Moreover, HyFoSy can be performed by a gynaecologist during a one-stop fertility work-up. To our knowledge, the costs of both strategies have never been compared., Study Design, Size, Duration: We performed an economic evaluation alongside the FOAM trial, a randomized multicenter study conducted in the Netherlands. Participating infertile women underwent, both HyFoSy and HSG, in a randomized order. The results of both tests were compared and women with discordant test results were randomly allocated to management based on the results of one of the tests. The follow-up period was twelve months., Participants/materials, Setting, Methods: We studied 1160 infertile women (18-41 years) scheduled for tubal patency testing. The primary outcome was ongoing pregnancy leading to live birth. The economic evaluation compared costs and effects of management based on either test within 12 months. We calculated incremental cost-effectiveness ratios (ICERs): the difference in total costs and chance of live birth. Data were analyzed using the intention to treat principle., Main Results and the Role of Chance: Between May 2015 and January 2019, 1026 of the 1160 women underwent both tubal tests and had data available: 747 women with concordant results (48% live births), 136 with inconclusive results (40% live births), and 143 with discordant results (41% had a live birth after management based on HyFoSy results versus 49% with live birth after management based on HSG results). When comparing the two strategies-management based on HyfoSy results versus HSG results-the estimated chance of live birth was 46% after HyFoSy versus 47% after HSG (difference -1.2%; 95% CI: -3.4% to 1.5%). For the procedures itself, HyFoSy cost €136 and HSG €280. When costs of additional fertility treatments were incorporated, the mean total costs per couple were €3307 for the HyFoSy strategy and €3427 for the HSG strategy (mean difference €-119; 95% CI: €-125 to €-114). So, while HyFoSy led to lower costs per couple, live birth rates were also slightly lower. The ICER was €10 042, meaning that by using HyFoSy instead of HSG we would save €10 042 per each additional live birth lost., Limitations, Reasons for Caution: When interpreting the results of this study, it needs to be considered that there was a considerable uncertainty around the ICER, and that the direct fertility enhancing effect of both tubal patency tests was not incorporated as women underwent both tubal patency tests in this study., Wider Implication of the Findings: Compared to clinical management based on HSG results, management guided by HyFoSy leads to slightly lower live birth rates (though not statistically significant) at lower costs, less pain, without ionizing radiation and iodinated contrast exposure. Further research on the comparison of the direct fertility-enhancing effect of both tubal patency tests is needed., Study Funding/competing Interest(s): FOAM trial was an investigator-initiated study, funded by ZonMw, a Dutch organization for Health Research and Development (project number 837001504). IQ Medical Ventures provided the ExEm®-FOAM kits free of charge. The funders had no role in study design, collection, analysis, and interpretation of the data. K.D. reports travel-and speakers fees from Guerbet and her department received research grants from Guerbet outside the submitted work. H.R.V. received consulting-and travel fee from Ferring. A.M.v.P. reports received consulting fee from DEKRA and fee for an expert meeting from Ferring, both outside the submitted work. C.H.d.K. received travel fee from Merck. F.J.M.B. received a grant from Merck and speakers fee from Besins Healthcare. F.J.M.B. is a member of the advisory board of Merck and Ferring. J.v.D. reported speakers fee from Ferring. J.S. reports a research agreement with Takeda and consultancy for Sanofi on MR of motility outside the submitted work. M.v.W. received a travel grant from Oxford Press in the role of deputy editor for Human Reproduction and participates in a DSMB as independent methodologist in obstetrics studies in which she has no other role. B.W.M. received an investigator grant from NHMRC GNT1176437. B.W.M. reports consultancy for ObsEva, Merck, Guerbet, iGenomix, and Merck KGaA and travel support from Merck KGaA. V.M. received research grants from Guerbet, Merck, and Ferring and travel and speakers fees from Guerbet. The other authors do not report conflicts of interest., Trial Registration Number: International Clinical Trials Registry Platform No. NTR4746., (© The Author(s) 2024. Published by Oxford University Press on behalf of European Society of Human Reproduction and Embryology.)
- Published
- 2024
- Full Text
- View/download PDF
47. Development and Validation of the Scoring System of Appendicitis Severity 2.0.
- Author
-
Scheijmans JCG, Bom WJ, Ghori UH, van Geloven AAW, Hannink G, van Rossem CC, van de Wouw L, Huisman PM, van Hemert A, Franken RJ, Oosterling SJ, Rosman C, Koens L, Stoker J, Dijkgraaf MGW, and Boermeester MA
- Subjects
- Humans, Female, Male, Adult, Prospective Studies, Middle Aged, Netherlands, Appendectomy, Predictive Value of Tests, Appendicitis diagnosis, Appendicitis complications, Severity of Illness Index
- Abstract
Importance: When considering nonoperative treatment in a patient with acute appendicitis, it is crucial to accurately rule out complicated appendicitis. The Atema score, also referred to as the Scoring System of Appendicitis Severity (SAS), has been designed to differentiate between uncomplicated and complicated appendicitis but has not been prospectively externally validated., Objective: To externally validate the SAS and, in case of failure, to develop an improved SAS (2.0) for estimating the probability of complicated appendicitis., Design, Setting, and Participants: This prospective study included adult patients who underwent operations for suspected acute appendicitis at 11 hospitals in the Netherlands between January 2020 and August 2021., Main Outcomes and Measures: Appendicitis severity was predicted according to the SAS in 795 patients and its sensitivity and negative predictive value (NPV) for complicated appendicitis were calculated. Since the predefined targets of 95% for both were not met, the SAS 2.0 was developed using the same cohort. This clinical prediction model was developed with multivariable regression using clinical, biochemical, and imaging findings. The SAS 2.0 was externally validated in a temporal validation cohort consisting of 565 patients., Results: In total, 1360 patients were included, 463 of whom (34.5%) had complicated appendicitis. Validation of the SAS resulted in a sensitivity of 83.6% (95% CI, 78.8-87.6) and an NPV of 85.0% (95% CI, 80.6-88.8), meaning that the predefined targets were not achieved. Therefore, the SAS 2.0 was developed, internally validated (C statistic, 0.87; 95% CI, 0.84-0.89), and subsequently externally validated (C statistic, 0.86; 95% CI, 0.82-0.89). The SAS 2.0 was designed to calculate a patient's individual probability of having complicated appendicitis along with a 95% CI., Conclusions and Relevance: In this study, external validation of the SAS fell short in accurately distinguishing complicated from uncomplicated appendicitis. The newly developed and externally validated SAS 2.0 was able to assess an individual patient's probability of having complicated appendicitis with high accuracy in patients with acute appendicitis. Use of this patient-specific risk assessment tool can be helpful when considering and discussing nonoperative treatment of acute appendicitis with patients.
- Published
- 2024
- Full Text
- View/download PDF
48. Free-breathing motion corrected magnetic resonance elastography of the abdomen.
- Author
-
van Schelt AS, Wassenaar NPM, Runge JH, Nelissen JL, van Laarhoven HWM, Stoker J, Nederveen AJ, and Schrauben EM
- Abstract
Background: Magnetic resonance elastography (MRE) is a non-invasive method to measure the viscoelastic properties of tissue and has been applied in multiple abdominal organs. However, abdominal MRE suffers from detrimental breathing motion causing misalignment of structures between repeated acquisitions for different MRE dimensions (e.g., motion encoding directions and wave phase offsets). This study investigated motion correction strategies to resolve all breathing motion on sagittal free-breathing MRE acquisitions in a phantom, in healthy volunteers and showed feasibility in patients., Methods: First, in silico experiments were performed on a static phantom dataset with simulated motion. Second, eight healthy volunteers underwent two sagittal MRE acquisitions in the pancreas and right kidney. The multi-frequency free-breathing spin-echo echo-planar-imaging (SE-EPI) MRE consisted of four frequencies (30, 40, 50, 60 Hz), eight wave-phase offsets, with 3 mm
3 isotropic voxel size. Following data re-sorting in different number of motion states (4 till 12) based on respiratory waveform signal, three intensity-based registration methods (monomodal, multimodal, and phase correlation) and non-rigid local registration were compared. A ranking method was used to determine the best registration method, based on seven signal-to-noise and image quality measures. Repeatability was assessed for no motion correction (Original) and the best performing method (Best) using Bland-Altman analysis. Lastly, the best motion correction method was compared to no motion correction on patient MRE data [pancreatic ductal adenocarcinoma (PDAC, n=5) and metabolic dysfunction-associated steatotic liver disease (MASLD) (n=1)]., Results: In silico experiments showed a deviation of shear wave speed (SWS) with simulated motion to the ground truth, which was (partially) resolved using motion correction. In healthy volunteers ranking resulted in the best motion correction method of monomodal registration using nine motion states, while no motion correction was ranked last. Limits of agreement were (-0.18, 0.14), and (-0.25, 0.18) m/s for Best and Original, respectively. Using motion correction in patients resulted in a significant increase in SWS in the pancreas (Original: 1.39±0.10 and Best: 1.50±0.17 m/s). After motion correction PDAC had a mean SWS of 1.56±0.27 m/s (Original: 1.42±0.25 m/s). The fibrotic liver mean SWS was 2.07±0.20 m/s (Original: 2.12±0.18 m/s)., Conclusions: Motion correction in sagittal free-breathing abdominal MRE results in improved data quality, inversion precision, repeatability, and is feasible in patients., Competing Interests: Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://qims.amegroups.com/article/view/10.21037/qims-23-1727/coif). The authors have no conflicts of interest to declare., (2024 Quantitative Imaging in Medicine and Surgery. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF
49. MR Elastography of the Pancreas: Bowel Preparation and Repeatability Assessment in Pancreatic Cancer Patients and Healthy Controls.
- Author
-
Wassenaar NPM, van Schelt AS, Schrauben EM, Kop MPM, Nio CY, Wilmink JW, Besselink MGH, van Laarhoven HWM, Stoker J, Nederveen AJ, and Runge JH
- Subjects
- Humans, Female, Middle Aged, Aged, Male, Magnetic Resonance Imaging methods, Prospective Studies, Pancreas diagnostic imaging, Reproducibility of Results, Water, Elasticity Imaging Techniques methods, Pancreatic Neoplasms diagnostic imaging
- Abstract
Background: Pancreatic ductal adenocarcinoma (PDAC) stromal viscoelasticity can be measured using MR elastography (MRE). Bowel preparation regimens could affect MRE quality and knowledge on repeatability is crucial for clinical implementation., Purpose: To assess effects of four bowel preparation regimens on MRE quality and to evaluate repeatability and differentiate patients from healthy controls., Study Type: Prospective., Population: 15 controls (41 ± 16 years; 47% female), 16 PDAC patients (one excluded, 66 ± 12 years; 40% female) with 15 age-/sex-matched controls (65 ± 11 years; 40% female). Final sample size was 25 controls and 15 PDAC., Field Strength/sequence: 3-T, spin-echo echo-planar-imaging, turbo spin-echo, and fast field echo gradient-echo., Assessment: Four different regimens were used: fasting; scopolaminebutyl; drinking 0.5 L water; combination of 0.5 L water and scopolaminebutyl. MRE signal-to-noise ratio (SNR) was compared between all regimens. MRE repeatability (test-retest) and differences in shear wave speed (SWS) and phase angle (ϕ) were assessed in PDAC and controls. Regions-of-interest were defined for tumor, nontumorous (n = 8) tissue in PDAC, and whole pancreas in controls. Two radiologists delineated tumors twice for evaluation of intraobserver and interobserver variability., Statistical Tests: Repeated measures analysis of variance, coefficients of variation (CoVs), Bland-Altman analysis, (un)paired t-test, Mann-Whitney U-test, and Wilcoxon signed-rank test. P-value<0.05 was considered statistically significant., Results: Preparation regimens did not significantly influence MRE-SNR. Therefore, the least burdensome preparation (fasting only) was continued. CoVs for tumor SWS were: intrasession (12.8%) and intersession (21.7%), and intraobserver (7.9%) and interobserver (10.3%) comparisons. For controls, CoVs were intrasession (4.6%) and intersession (6.4%). Average SWS for tumor, nontumor, and healthy tissue were: 1.74 ± 0.58, 1.38 ± 0.27, and 1.18 ± 0.16 m/sec (ϕ: 1.02 ± 0.17, 0.91 ± 0.07, and 0.85 ± 0.08 rad), respectively. Significant differences were found between all groups, except for ϕ between healthy-nontumor (P = 0.094)., Data Conclusion: The proposed bowel preparation regimens may not influence MRE quality. MRE may be able to differentiate between healthy tissue-tumor and tumor-nontumor., Level of Evidence: 2 TECHNICAL EFFICACY STAGE: 2., (© 2023 The Authors. Journal of Magnetic Resonance Imaging published by Wiley Periodicals LLC on behalf of International Society for Magnetic Resonance in Medicine.)
- Published
- 2024
- Full Text
- View/download PDF
50. [ 18 F]FDG-PET/CT-based risk stratification in women with locally advanced uterine cervical cancer.
- Author
-
Adam JA, Poel E, van Eck Smit BLF, Mom CH, Stalpers LJA, Laan JJ, Kidd E, Stoker J, and Bipat S
- Subjects
- Humans, Female, Middle Aged, Retrospective Studies, Adult, Aged, Risk Assessment methods, Chemoradiotherapy, Radiopharmaceuticals, Aged, 80 and over, Prognosis, Uterine Cervical Neoplasms diagnostic imaging, Uterine Cervical Neoplasms pathology, Uterine Cervical Neoplasms mortality, Uterine Cervical Neoplasms therapy, Positron Emission Tomography Computed Tomography methods, Fluorodeoxyglucose F18, Neoplasm Staging
- Abstract
Background: [
18 F]FDG-PET/CT is used for staging and treatment planning in patients with locally advanced cervical cancer (LACC). We studied if a PET-based prediction model could provide additional risk stratification beyond International Federation of Gynaecology and Obstetrics (FIGO) staging in our population with LACC to aid treatment decision making., Methods: In total, 183 patients with LACC treated with chemoradiation between 2013 and 2018 were included. Patients were treated according to FIGO 2009 and retrospectively reclassified according to FIGO 2018 staging system. After validation of an existing PET-based prediction model, the predicted recurrent free survival (RFS), disease specific survival (DSS) and overall survival (OS) at 1, 3, and 5 years, based on metabolic tumor volume (MTV), maximum standardized uptake value (SUVmax ) and highest level of [18 F]FDG-positive node was calculated. Then the observed survival was compared to the predicted survival. An area under the curve (AUC) close to or higher than 0.7 was considered adequate for accurate prediction. The Youden (J) index defined survival chance cutoff values for low and high risk groups., Results: All AUC values for the comparison between predicted and observed outcomes were > 0.7 except for 5-year RFS and for 5-year OS which were close to 0.7 (0.684 and 0.650 respectively). Cutoff values for low and high risk survival chance were 0.44 for the 3-year RFS and 0.47 for the 5-year OS. The FIGO 2009 system could not differentiate between the risk profiles. After reclassification according to FIGO 2018, all patients with stage IIIC2 and IVB fell in the high risk and almost all patients with stages IB2-IIIB and IVA in the low risk group. In patients with stage IIIC1 disease the FIGO stage cannot discriminate between the risk profiles., Conclusions: Low and high risk patients with LACC can be identified with the PET-based prediction model. In particular patients with stage IIIC1 need additional risk stratification besides the FIGO 2018 staging. The Kidd model could be a useful tool to aid treatment decision making in these patients. Our results also support the choice of [18 F]FDG-PET/CT imaging in patients with LACC., (© 2024. The Author(s).)- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.